CSPC PHARMA: The new drug application for Idaglutide α injection has been accepted by the National Medical Products Administration
I'm PortAI, I can summarize articles.
CSPC PHARMA announced that the new drug application for its subsidiary's developed injectable EdaGlutide α has been accepted by the National Medical Products Administration. This product is used for long-term weight management in overweight or obese adults, demonstrating significant effects in reducing weight and improving cardiovascular and metabolic indicators. Clinical trials have shown good safety and tolerability, with a low incidence of adverse events. The Phase III clinical trial for this product is currently ongoing
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments